🇺🇸 FDA
Pipeline program

Calquence 100 mg film-coated tablets, Calquence 100 mg film-coated tablets

D8223C00016

Approved small_molecule active

Quick answer

Calquence 100 mg film-coated tablets, Calquence 100 mg film-coated tablets for Chronic Lymphocytic Leukaemia and Moderate to Severe Cardiac Impairment is a Approved program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca AB
Indication
Chronic Lymphocytic Leukaemia and Moderate to Severe Cardiac Impairment
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials